Project Grant DP2DA060600
Award Date
7/1/24
Completion Date
6/30/28
Dollars Obligated
$4.9M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This $3,866,705 federal Project Grant award was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports the "LONG-ACTING INJECTABLES FOR TREATMENT OF HIV AMONG PWID (LIFT HIV)" project, which aims to develop new approaches for achieving sustained viral suppression among people who inject drugs (PWID) living with HIV. The primary awardee, The Johns Hopkins University, will conduct research, clinical...
This $1,192,612 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The key products and services to be delivered include:
A systematic assessment of healthcare utilization, HIV prevention services, and medication for OUD (MOUD) using claims data to identify care settings for integrating HIV...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,260,957 to the Research Foundation of the City University of New York (RFCUNY) to conduct research on optimizing long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) strategies for sexual minority men (SMM) who use methamphetamine.
The key objectives are to: 1) conduct qualitative interviews to gather insights on care...
This $2,426,074 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Federal Grant Program for Drug Use and Addiction Research Programs (CFDA 93.279) aims to study the effects of different medications for opioid use disorder (MOUD) on immune activation and neurocognition in people living with HIV (PLWH).
The research will longitudinally assess cerebrospinal fluid biomarkers of neuroinflammation, neuronal injury, and myeloid cell activation in PLWH receiving either...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,607,146 to NDRI-USA Inc. to develop community-based technology interventions that aim to increase protective behaviors against drug overdose, including drug checking, distribution of harm reduction supplies, and linkage to services. The project will employ a participatory design process to create new educational materials in English and Spanish...
This $2,316,128 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to design tailored harm reduction strategies to address the overdose crisis in six distinct jurisdictions. The project, titled "REVERSING OVERDOSE EPIDEMICS THROUGH SIMULATION, COLLABORATION, AND UNIFIED EFFORTS (RESCUE)", will collaborate with health departments and community partners to assess the effectiveness,...
This federal Project Grant award of $2,214,862 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is supporting a study to optimize the implementation and evaluate the effectiveness of co-packaging long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) and buprenorphine for opioid use disorder (OUD) in carceral and community re-entry settings in Maryland and Washington, D.C. The project aims to develop the intervention...
The National Institute on Drug Abuse awarded a $1,533,697 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation. The grant will fund a study to test an innovative, peer-driven "intravention" approach to engage people who use drugs in harm reduction service delivery and reduce the risk of HIV, hepatitis C, overdose, and injection-related infections in rural Appalachia. The proposed project will partner with...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $360,720 to conduct a randomized controlled trial examining the use of extended-release injectable buprenorphine compared to sublingual buprenorphine/naloxone for the treatment of opioid use disorder in individuals who use high-potency synthetic opioids. The primary objectives are to compare abstinence and relapse rates between the two...
This award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,463,190 in funding to The Johns Hopkins University to conduct a study examining longitudinal changes in the associations between the frequency and types of engagements with medications for opioid use disorder (MOUD), harm reduction, and law enforcement, HIV risk behaviors, and HIV incidence among a cohort of 400 rural people who inject drugs (PWID) over an...